Eur J Cancer. 1992;28(2-3):415-20.
An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients.
Dowsett M, Mehta A, King N, Smith IE, Powles TJ, Stein RC, Coombes RC.
Department of Academic Biochemistry, Royal Marsden Hospital, London, U.K.
43 postmenopausal breast cancer patients were treated orally with the aromatase inhibitor formestane (4-hydroxyandrostenedione) at daily doses of 62.5, 125, 250 or 500 mg for 4 weeks followed by 250 mg daily for a further 4 weeks. For some patients, 62.5 mg did not suppress serum oestradiol levels maximally. The doses of 250 and 500 mg did not differ in their effectiveness. Oestrone levels were suppressed by all doses of formestane but no consistent changes of aldosterone, cortisol or 17-hydroxyprogesterone occurred. Serum levels of sex hormone binding globulin fell by about 15% during treatment with 250 mg formestane reflecting its minor androgenic activity. The maximum concentration and area under the curve of serum formestane levels after the first dose varied in an approximately linear manner with dose. It is concluded that formestane is an effective, specific suppressant of oestradiol levels via the oral route requiring no more than 250 mg to be given daily.
PMID: 1591054 [PubMed - indexed for MEDLINE]